Download PDF
Seminars in Neurosurgery 2002; 13(3): 203-216
DOI: 10.1055/s-2002-39938
Copyright © 2002 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

The Role of Inflammation in Atherosclerosis

Thomas J. DeGraba
  • Clinical Stroke Research Unit, National Naval Medical Center, Bethesda, Maryland, and National Institute of Neurological Disorders and Stroke, Bethesda, Maryland
Further Information

Publication History

Publication Date:
24 June 2003 (online)

    Permissions and Reprints

ABSTRACT

The evolving literature clearly indicates that atherosclerosis represents a chronic inflammatory process that increases the risk for intraluminal thrombosis and incidence of ischemic stroke and heart attack. The understanding of the immune system's role in the pathophysiology of atherosclerosis will help to modify our utilization of medications that minimize the influence of the inflammatory character of the plaque and potentially reduce the risk of plaque destabilization and thromboembolic events. Recognition of biological markers and susceptibility genes will further improve the ability to predict the at-risk population and target susceptible patient populations to early interventional therapeutic modalities.

KEYWORDS

Atherosclerosis - inflammation - infection - therapy - C-reactive protein - T-lymphocytes

REFERENCES

  • 1 Gillum R F, Sempas C T. The end of the long-term decline in stroke mortality in the United States?.  Stroke . 1997;  28 1527-1529
    PubMedGoogle Scholar
  • 2 North American Symptomatic Carotid Endarterectomy Trial Collaborators. Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis.  N Engl J Med . 1991;  325 445-453
    CrossrefPubMedGoogle Scholar
  • 3 Toole J F, on behalf of the ACAS Executive Committee. ACAS recommendations for carotid endarterectomy.  Lancet . 1996;  347 121
    PubMedGoogle Scholar
  • 4 Libby P. Coronary artery injury and the biology of atherosclerosis: inflammation, thrombosis, and stabilization.  Am J Cardiol . 2000;  86 3J-9J
    PubMedGoogle Scholar
  • 5 Benveniste E N. Inflammatory cytokines within the central nervous system: source, function, and mechanism of action.  Am J Physiol . 1992;  263 C1-16
    PubMedGoogle Scholar
  • 6 Hallenbeck J M. Inflammatory reactions at the blood-endothelial interface in acute stroke.  Adv Neurol . 1996;  71 281-300
    PubMedGoogle Scholar
  • 7 Rothwell N J, Loddick S A, Stroemer P. Interleukins and cerebral ischemia.  Int Rev Neurobiol . 1997;  40 281-298
    PubMedGoogle Scholar
  • 8 Bevilacqua M P, Pober J S, Majeau G R, Cotran R S, Gimbrone Jr A R. Interleukin-1 (IL-1) induces biosynthesis and cell surface expression of pro-coagulant activity in human vascular endothelial cells.  J Exp Med . 1984;  160 618-623
    CrossrefPubMedGoogle Scholar
  • 9 Nawroth P P, Handley D A, Esmon C T, Stern D M. Interleukin-1 induces endothelial cell procoagulant while suppressing cell-surface anticoagulant activity.  Proc Natl Acad Sci USA . 1986;  83 3460-3464
    PubMedGoogle Scholar
  • 10 Nawroth P P, Stern D M. Modulation of endothelial cell hemostatic properties by tumor necrosis factor.  J Exp Med . 1986;  163 740-745
    CrossrefPubMedGoogle Scholar
  • 11 DeGraba T J, Sirén A-L, Penix L. et al . Increased endothelial expression of intercellular adhesion molecule-1 (ICAM-1) in symptomatic vs asymptomatic human atherosclerotic plaque.  Stroke . 1998;  29 1405-1410
    PubMedGoogle Scholar
  • 12 Jander S, Sitzer M, Schumann R. et al . Inflammation in high-grade carotid stenosis: a possible role for macrophages and T cells in plaque destabilization.  Stroke . 1998;  29 1625-1630
    PubMedGoogle Scholar
  • 13 van der Wal C A, Becker A E, van de Loos M C, Das P K. Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology.  Circulation . 1994;  89 36-44
    PubMedGoogle Scholar
  • 14 Morigi M, Zoja C, Figliuzzi M. et al . Fluid shear stress modulates surface expression of adhesion molecules by endothelial cells.  Blood . 1995;  85 1696-1703
    PubMedGoogle Scholar
  • 15 Malek A M, Jackman R, Rosenberg R D, Izumo S. Endothelial expression of thrombomodulin is reversibly regulated by fluid shear stress.  Circ Res . 1994;  74 852-860
    PubMedGoogle Scholar
  • 16 Steinberg D, Parthasarathy S, Carew T E, Khoo J C, Witztum J L. Beyond cholesterol: modifications of low-density lipoprotein that increase its atherogenicity.  N Engl J Med . 1989;  320 915-924
    CrossrefPubMedGoogle Scholar
  • 17 Stemme S, Faber B, Holm J, Wiklund O, Witztum J L, Hansson G K. T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein.  Proc Natl Acad Sci USA . 1995;  92 3893-3897
    PubMedGoogle Scholar
  • 18 Zhu B, Sun Y, Sievers R E, Isenberg W M, Glantz S A, Parmelye W W. Passive smoking increases experimental atherosclerosis in cholesterol-fed rabbits.  J Am Coll Cardiol . 1993;  21 225-232
    PubMedGoogle Scholar
  • 19 Miller G J, Bauer K A, Cooper J A, Rosenberg R D. Activation of the coagulant pathway in cigarette smokers.  Thromb Haemost . 1998;  79 549-553
    PubMedGoogle Scholar
  • 20 Newby D E, Wright R A, Labinjoh C. et al . Endothelial dysfunction, impaired endogenous fibrinolysis, and cigarette smoking.  Circulation . 1999;  99 1411-1415
    PubMedGoogle Scholar
  • 21 Zidovetzki R, Chen P, Fisher M, Hofman F M. Nicotine increases plasminogen activator inhibitor-1 production by human brain endothelial cells via protein kinase C-associated pathway.  Stroke . 1999;  30 651-655
    PubMedGoogle Scholar
  • 22 Markovitz J H, Tolbert L, Winders S E. Increased serotonin receptor density and platelet GPIIb/IIIa activation among smokers.  Arterioscler Thromb Vasc Biol . 1999;  19 762-766
    PubMedGoogle Scholar
  • 23 Matetzky S, Tani S, Kangavari S. et al . Smoking increases tissue factor expression in atherosclerotic plaques: implications for plaque thrombogenicity.  Circulation . 2000;  102 602-604
    PubMedGoogle Scholar
  • 24 Celermajer D S, Adams M R, Clarkson P. et al . Passive smoking and impaired endothelium-dependent arterial dilatation in healthy young adults.  N Engl J Med . 1996;  334 150-154
    CrossrefPubMedGoogle Scholar
  • 25 Hutchison S J, Sudhir K, Sievers R E. et al . Effects of L-arginine on atherogenesis and endothelial dysfunction due to secondhand smoke.  Hypertension . 1999;  34 44-50
    PubMedGoogle Scholar
  • 26 Benowitz N L, Fitzgerald G A, Wilson M, Zhang Q. Nicotine effects on eicosanoid formation and hemostatic function: comparison of transdermal nicotine and cigarette smoking.  J Am Coll Cardiol . 1993;  22 1159-1167
    PubMedGoogle Scholar
  • 27 Patiño R, Ibarra J, Rodriguez A. et al . Circulating monocytes in patients with diabetes mellitus, arterial disease, and increased CD14 expression.  Am J Cardiol . 2000;  85 1288-1291
    CrossrefPubMedGoogle Scholar
  • 28 Marfella R, Esposito K, Giunta R. et al . Circulating adhesion molecules in humans: role of hyperglycemia and hyperinsulinemia.  Circulation . 2000;  101 2247-2251
    PubMedGoogle Scholar
  • 29 The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.  N Engl J Med . 2000;  342 145-153
    CrossrefPubMedGoogle Scholar
  • 30 Fukuhara M, Geary R L, Diz D I. et al . Angiotensin-converting enzyme expression in human carotid artery atherosclerosis.  Hypertension . 2000;  35[part 2] 353-359
    PubMedGoogle Scholar
  • 31 Dzau V J. Mechanism of protective effects of ACE inhibition on coronary artery disease.  Eur Heart J . 1998;  19 (suppl J) J2-J6
    PubMedGoogle Scholar
  • 32 Andersen S, Schalkwijk C G, Stehouwer R CD, Parving H H. Angiotensin-II blockade is associated with decreased plasma leukocyte adhesion molecule levels in diabetic nephropathy.  Diabetes Care. 2000;  23 1031-1032
    PubMedGoogle Scholar
  • 33 Fitzgerald J D. By what means might beta-blockers prolong life after acute myocardial infarction?.  Eur Heart J. 1987;  3 945-951
    PubMedGoogle Scholar
  • 34 Scandinavian Simvastatin Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S).  Lancet . 1994;  344 1383-1389
    PubMedGoogle Scholar
  • 35 Sacks F M, Pfeffer M A, Moye L A, for the Recurrent Events Trial Investigators. et al . The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels.  N Engl J Med . 1996;  335 1001-1009
    CrossrefPubMedGoogle Scholar
  • 36 Ridker P M, Rifai N, Pfeffer M A. et al . Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators.  Circulation . 1998;  98 839-844
    PubMedGoogle Scholar
  • 37 Romano M, Diomede L, Sironi M. et al . Inhibition of monocyte chemotactic protein-1 synthesis by statins.  Lab Invest . 2000;  80 1095-1100
    PubMedGoogle Scholar
  • 38 Bustos C, Hernandez-Presa M A, Orgego M. et al . HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis.  J Am Coll Cardiol . 1998;  32 2057-2064
    CrossrefPubMedGoogle Scholar
  • 39 Kothe H, Dalhoff K, Rupp J. et al . Hydroxymethylglutaryl coenzyme A reductase inhibitors modify the inflammatory response of human macrophages and endothelial cells infected with Chlamydia pneumoniae Circulation .  2000;  101 1760-1763
    PubMedGoogle Scholar
  • 40 Vaughan C J, Gotto Jr M A, Basson C T. The evolving role of statins in the management of atherosclerosis.  J Am Coll Cardiol . 2000;  35 1-10
    CrossrefPubMedGoogle Scholar
  • 41 Crisby J, Nordin-Fredriksson G, Shah P K, Yano J, Zhu J, Nilsson J. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques.  Circulation . 2001;  103 926-933
    PubMedGoogle Scholar
  • 42 Ridker P M, Rifai N, Pfeffer M A, Sacks F, Braunwald E, for the Cholesterol and Recurrent Events (CARE) Investigators. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators.  Circulation . 1999;  100 230-235
    PubMedGoogle Scholar
  • 43 Hackam D G, Peterson J C, Spence J D. What level of plasma homocyst(e)ine should be treated?: Effects of vitamin therapy on progression of carotid atherosclerosis in patients with homocyst(e)ine levels above and below 14 μmol/L.  Am J Hypertens. 2000;  13 105-110
    CrossrefPubMedGoogle Scholar
  • 44 Woodside J V, Yarnell J W, McMaster D. et al . Effect of B-group vitamins and antioxidant vitamins on hyperhomocystinemia: a double-blind, randomized, factorial-design, controlled trial.  Am J Clin Nutr. 1998;  67 858-866
    PubMedGoogle Scholar
  • 45 Spence J D, Howard V J, Chambless L E. et al . Vitamin Intervention for Stroke Prevention (VISP) trial: rationale and design.  Neuroepidemiology . 2001;  20 16-25
    CrossrefPubMedGoogle Scholar
  • 46 Gerhard G T, Duell P B. Homocysteine and atherosclerosis.  Curr Opin Lipidol . 1999;  10 417-428
    CrossrefPubMedGoogle Scholar
  • 47 Liao K, Yin M. Individual and combined antioxidant effects of seven phenolic agents in human erythrocyte membrane ghosts and phosphatidylcholine liposome systems: importance of the partition coefficient.  J Agric Food Chem . 2000;  48 2266-2270
    CrossrefPubMedGoogle Scholar
  • 48 Hamilton I MJ, Gilmore W S, Benzie I FF, Mulholland C W, Strain J J. Interactions between vitamins C and E in human subjects.  Br J Nutr . 2000;  84 261-267
    PubMedGoogle Scholar
  • 49 Carretro O A, Miyazaki S, Scidli A G. Role of kinins in the acute anti-hypertensive effect of converting enzyme inhibitor, Captopril.  Hypertension . 1985;  3 8-22
    PubMedGoogle Scholar
  • 50 Baur L H, Schipperheyn J J, van der Laarse A. et al . Combining salicylate and enalapril in patients with coronary artery disease and heart failure.  Br Heart J . 1995;  73 227-236
    PubMedGoogle Scholar
  • 51 van Wijngaarden J, Smit A J, de Graeff A P. et al . Effects of acetylsalicylic acid on peripheral hemodynamics in patients with chronic heart failure treated with angiotensin-converting enzyme inhibitors.  J Cardiovasc Pharmacol . 1994;  23 240-245
    PubMedGoogle Scholar
  • 52 Weksler B B, Pett S B, Alonso D. et al . Differential inhibition by aspirin of vascular and platelet prostaglandin synthesis in atherosclerotic patients.  N Engl J Med. 1983;  308(14) 800-805
    CrossrefPubMedGoogle Scholar
  • 53 Katz S D, Radin M, Graves T, Hauck C, Block A, LeJemtel T H. Effect of aspirin and ifetroban on skeletal muscle blood flow in patients with congestive heart failure treated with Enalapril. Ifetroban Study Group.  J Am Coll Cardiol. 1999;  34 170-176
    CrossrefPubMedGoogle Scholar
  • 54 Catella-Lawson F, Reilly M P, Kapoor S C. et al . Cyclooxygenase inhibitors and the antiplatelet effects of aspirin.  N Engl J Med . 2001;  345 1809-1817
    CrossrefPubMedGoogle Scholar
  • 55 Ouellet M, Riendeau D, Percival M D. A high level of cyclooxygenase-2 inhibitor selectivity is associated with a reduced interference of platelet cyclooxygenase-1 inactivation by aspirin.  Proc Natl Acad Sci USA . 2001;  98 14583-14588
    CrossrefPubMedGoogle Scholar
  • 56 Mukherjee D, Nissen S E, Topol E EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors.  JAMA . 2001;  286 954-959
    CrossrefPubMedGoogle Scholar
  • 57 White W B, Faich G, Whelton A. et al . Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase-2 specific inhibitor, versus ibuprofen or diclofenac.  Am J Cardiol . 2002;  89 425-430
    PubMedGoogle Scholar
  • 58 Tataru M C, Heinrich J, Junker R. et al . C-reactive protein and the severity of atherosclerosis in myocardial infarction patients with stable angina pectoris.  Eur Heart J . 2000;  21 1000-1008
    CrossrefPubMedGoogle Scholar
  • 59 Rohde L E, Lee R T, Rivero J. et al . Circulating cell adhesion molecules are correlated with ultrasound-based assessment of carotid atherosclerosis.  Arterioscler Thromb Vasc Biol . 1998;  18 1765-1770
    PubMedGoogle Scholar
  • 60 Ridker P M, Rifai N, Pfeffer M, Sacks F, Lepage S, Braunwald E. Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction.  Circulation . 2000;  101 2149-2153
    CrossrefPubMedGoogle Scholar
  • 61 Hwang S J, Ballantyne C M, Sharrett A R. et al . Circulating adhesion molecules VCAM-1, ICAM-1 and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the atherosclerosis risk in communities (ARIC) study.  Circulation . 1997;  96 4219-4225
    PubMedGoogle Scholar
  • 62 Ridker P M. High sensitivity C-reactive protein.  Circulation . 2001;  103 1813-1818
    CrossrefPubMedGoogle Scholar
  • 63 Ridker P M, Cushman M, Stanpfer M J, Tracy R P, Hennekens C H. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.  N Engl J Med . 1997;  336 973-979
    CrossrefPubMedGoogle Scholar
  • 64 Downs J R, Clearfield M, Weis S. et al . Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.  JAMA . 1998;  279 1615-1622
    CrossrefPubMedGoogle Scholar
  • 65 Pasceri V, Chang J, Willerson J T, Yeh E TH. Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs.  Circulation . 2001;  103 2531-2534
    CrossrefPubMedGoogle Scholar
  • 66 Ridker P M, Rifai N, Pfeffer M A, Sacks F, Braunwald E, for the Cholesterol and Recurrent Events (CARE) Investigators. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators.  Circulation . 1999;  100 230-235
    PubMedGoogle Scholar
  • 67 Ridker P M, Cushman M, Stampfer M J, Tracy R P, Hennekens C H. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.  N Engl J Med . 1997;  336 973-979
    CrossrefPubMedGoogle Scholar
  • 68 Musial J, Undas A, Gajewski P, Jankowski M, Sydor W, Szczeklik A. Anti-inflammatory effects of simvastatin in subjects with hypercholesterolemia.  Int J Cardiol . 2001;  77 247-253
    CrossrefPubMedGoogle Scholar
  • 69 Morris M S, Jacques P F, Rosenberg I H. et al . Serum total homocysteine concentration is related to self-reported heart attack or stroke history among men and women in the NHANES III.  J Nutr . 2000;  130 3073-3076
    PubMedGoogle Scholar
  • 70 Libby P, Egan D, Skarlatos S. Roles of infectious agents in atherosclerosis and re-stenosis: an assessment of the evidence and need for future research.  Circulation . 1997;  96 4095-4103
    PubMedGoogle Scholar
  • 71 Epstein S E, Zhou Y F, Zhu J. Infection and atherosclerosis: emerging mechanistic paradigms.  Circulation . 1999;  100 E20-E28
    PubMedGoogle Scholar
  • 72 Vercellotti G. Infectious agents that play a role in atherosclerosis and vasculopathies: what are they?.  <~>What do we do about them? Can J Cardiol . 1999;  15 (suppl B) 13B-15B
    PubMedGoogle Scholar
  • 73 Nieto F J, Adam E, Sorlie P. et al . Cohort study of cytomegalovirus infection as a risk factor for carotid intimal-medial thickening, a measure of subclinical atherosclerosis.  Circulation . 1996;  94 922-927
    PubMedGoogle Scholar
  • 74 Sorlie P D, Adam E, Melnick S L. et al . Cytomegalovirus/ herpes virus and carotid atherosclerosis: the ARIC Study.  J Med Virol . 1994;  42 33-37
    PubMedGoogle Scholar
  • 75 Whincup P H, Mendall M A, Perry I J, Strachan D P, Walker M. Prospective relations between Helicobacter pylori infection, coronary heart disease, and stroke in middle-aged men.  Heart . 1996;  75 568-572
    CrossrefPubMedGoogle Scholar
  • 76 Patel P, Mendall M A, Carrington D. et al . Association of Helicobacter pylori and Chlamydia pneumoniae infections with coronary heart disease and cardiovascular risk factors.  BMJ . 1995;  311 711-714
    PubMedGoogle Scholar
  • 77 Ponzetto A, La Rovere T M, Sanseverino P, Bazzoli F. Association of Helicobacter pylori with coronary heart disease: study confirms previous findings.  BMJ . 1996;  312 251
    PubMedGoogle Scholar
  • 78 Beck J, Garcia R, Heiss G, Vokonas P S, Offenbacher S. Periodontal disease and cardiovascular disease.  J Periodontol . 1996;  67 1123-1137
    PubMedGoogle Scholar
  • 79 Span A H, vam Dam-Mieras C M, Mullers W, Endert J, Muller A D, Bruggeman C A. The effect of virus infection on the adherence of leukocytes or platelets to endothelial cells.  Eur J Clin Invest . 1991;  21 331-338
    PubMedGoogle Scholar
  • 80 Hajjar D P. Viral pathogenesis of atherosclerosis.  Am J Path . 1991;  139 1195-1211
    PubMedGoogle Scholar
  • 81 Minick C R, Fabricant C G, Fabricant J, Litrenta M M. Atheroarteriosclerosis induced by infection with a herpes virus.  Am J Path . 1979;  96 673-700
    PubMedGoogle Scholar
  • 82 Benditt E P, Barrett T, McDougall J K. Viruses in the etiology of atherosclerosis.  Proc Natl Acad Sci USA . 1983;  80 6386-6389
    PubMedGoogle Scholar
  • 83 Melnick J L, Adam E, Debakey M E. Possible role of cytomegalovirus in atherogenesis.  JAMA . 1990;  263 2204-2207
    CrossrefPubMedGoogle Scholar
  • 84 Zhu J, Quyyumi A A, Norman J E, Csako G, Epstein S E. Cytomegalovirus in the pathogenesis of atherosclerosis: the role of inflammation as reflected by elevated C-reactive protein levels.  J Am Coll Cardiol . 1999;  34 1738-1743
    CrossrefPubMedGoogle Scholar
  • 85 Ridker P M, Hennekens C H, Stampfer M J, Wang F. Prospective study of herpes simplex virus, cytomegalovirus, and the risk of future myocardial infarction and stroke.  Circulation . 1998;  98 2796-2799
    PubMedGoogle Scholar
  • 86 Ridker P M, Hennekens C H, Roitman-Johnson B, Stampfer M J, Allen J. Plasma concentration of soluble ICAM-1 and risk of future myocardial infarction in apparently healthy men.  Lancet . 1998;  351 88-92
    CrossrefPubMedGoogle Scholar
  • 87 Fagerberg B, Gnarpe J, Gnarpe H, Agewall S, Wikstrand J. Chlamydia pneumoniae but not cytomegalovirus antibodies are associated with future risk of stroke and cardiovascular disease.  Stroke . 1999;  30 299-305
    PubMedGoogle Scholar
  • 88 Speir E, Modali R, Huang E S. et al . Potential role of human cytomegalovirus and p53 interaction in coronary restenosis.  Science . 1994;  265 391-394
    PubMedGoogle Scholar
  • 89 Zhou Y F, Leon M B, Waclawiw M A. et al . Association between prior cytomegalovirus infection and the risk of restenosis after coronary atherectomy.  N Engl J Med . 1996;  335 624-630
    CrossrefPubMedGoogle Scholar
  • 90 Hendricks M G, Salimans M M, van Boven P C, Bruggeman C A. High prevalence of latently present cytomegalovirus in arterial walls of patients suffering from grade III atherosclerosis.  Am J Pathol . 1990;  136 23-28
    PubMedGoogle Scholar
  • 91 Lemstrom K B, Aho P T, Bruggeman C A, Hayry P J. Cytomegalovirus infection enhances mRNA expression of platelet-derived growth factor-BB and transforming growth factor-beta 1 in rat aortic allografts: possible mechanism for cytomegalovirus-enhanced graft arteriosclerosis.  Arterioscler Thromb . 1994;  14 2043-2052
    PubMedGoogle Scholar
  • 92 Geist L J, Monick M M, Stinski M F, Hunninghake G W. The immediate early genes of human cytomegalovirus upregulate tumor necrosis factor-alpha gene expression.  J Clin Invest . 1994;  93 474-478
    PubMedGoogle Scholar
  • 93 Kowalik T F, Wing B, Haskill J S, Azizkhan J C, Baldwin A S, Huang E S. Multiple mechanisms are implicated in the regulation of NF-B activity during human cytomegalovirus infection.  Proc Natl Acad Sci USA . 1993;  90 1107-1111
    PubMedGoogle Scholar
  • 94 Van Dam-Mieras C E M, Muller A D, van Hinsbergh W M V, Mullers W H A J, Bomans P HH, Bruggeman C A. The procoagulant response of cytomegalovirus infected endothelial cells.  Thromb Haemost . 1992;  68 364-370
    PubMedGoogle Scholar
  • 95 Eingen O R, Silverstein R L, Friedman H M, Hajjar D P. Viral activation of the coagulation cascade: molecular interactions at the surface of infected endothelial cells.  Cell . 1990;  61 657-662
    CrossrefPubMedGoogle Scholar
  • 96 Pryzdial E LG, Wright J F. Prothrombinase assembly on an enveloped virus: evidence that the cytomegalovirus surface contains procoagulant phospholipid.  Blood . 1994;  84 3749-3757
    PubMedGoogle Scholar
  • 97 Span A H, vam Dam-Mieras C M, Mullers W, Endert J, Muller A D, Bruggeman C A. The effect of virus infection on the adherence of leukocytes or platelets to endothelial cells.  Eur J Clin Invest . 1991;  21 331-338
    PubMedGoogle Scholar
  • 98 Grundy J E, Downes K L. Up-regulation of LFA-3 and ICAM-1 of the surface of fibroblasts infected with cytomegalovirus.  Immunology . 1993;  78 405-412
    PubMedGoogle Scholar
  • 99 Span A H, Mullers W, Miltenberg A M, Bruggeman C A. Cytomegalovirus induced PMN adherence in relation to an ELAM-1 antigen present on infected endothelial cell monolayers.  Immunology . 1991;  72 355-360
    PubMedGoogle Scholar
  • 100 LaBiche R, Koziol D, Quinn T. et al . Presence of Chlamydia pneumoniae in human symptomatic and asymptomatic carotid atherosclerotic plaque.  Stroke . 2001;  32 855-860
    PubMedGoogle Scholar
  • 101 Gaydos C A, Summersgill J T, Sahne N N, Ramirez J S, Quinn T. Replication of Chlamydia pneumoniae in vitro in human macrophages, endothelial cells, and aortic artery smooth muscle cells.  Infect Immun . 1996;  64 1614-1620
    PubMedGoogle Scholar
  • 102 Beatty W L, Byrne G I, Morrison R P. Repeated and persistent infection with Chlamydia and the development of chronic inflammation and disease.  Trends Microbiol . 1994;  2 94-98
    CrossrefPubMedGoogle Scholar
  • 103 Kol A, Sukhova G K, Lichtman A H, Libby P. Chlamydial heat shock protein 60 localizes in human atheroma and regulates macrophage tumor necrosis factor-α and matrix metalloproteinase expression.  Circulation . 1998;  98 300-307
    PubMedGoogle Scholar
  • 104 Rothermel C D, Schachter J, Lavrich P, Lipsitz E C, Francus T. Chlamydia trachomatis-induced production of interleukin-1 by human monocytes.  Infect Immun . 1989;  57 2705-2711
    PubMedGoogle Scholar
  • 105 Kalayoglu M V, Hoerneman B, LaVerda D, Morrison S G, Morrison R P, Byrne G I. Cellular oxidation of low density lipoprotein by Chlamydia pneumoniae J Infect Dis .  1999;  180 780-790
    CrossrefPubMedGoogle Scholar
  • 106 Kalayoglu M V, Byrne B I. Induction of macrophage foam cell formation by Chlamydia pneumoniae J Infect Dis .  1998;  177 725-729
    PubMedGoogle Scholar
  • 107 Papanicolaou D A, Wilder R L, Manolagas S C, Chrousos G P. The pathophysiologic roles of interleukin-6 in human disease.  Ann Intern Med . 1998;  128 127-137
    PubMedGoogle Scholar
  • 108 Watkins N G, Hadlow W J, Moos A B, Caldwell H D. Ocular delayed hypersensitivity: apathogenetic mechanism of chlamydial conjunctivitis in guinea pigs.  Proc Natl Acad Sci USA . 1986;  83 7480-7487
    PubMedGoogle Scholar
  • 109 Morrison R P, Belland R J, Lyng K, Caldwell H D. Chlamydial disease pathogenesis.  the 57-kD chlamydial hypersensitivity antigen is a stress response protein. J Exp Med . 1989;  170 1271-1283
    PubMedGoogle Scholar
  • 110 Laitinen K, Aluria A, Pyhala L, Leinonen M, Saikku P. Chlamydia pneumoniae infection induces inflammatory changes in the aortas of rabbits.  Infect Immun . 1997;  65 4832-4835
    PubMedGoogle Scholar
  • 111 Fong I W, Chiu B, Viira E, Fong M W, Jang D, Mahony J. Rabbit model for Chlamydia pneumoniae infection.  J Clin Microbiol . 1997;  35 48-52
    PubMedGoogle Scholar
  • 112 Moazed T C, Campbell L A, Rosenfeld M E, Grayston J T, Kuo C C. Chlamydia pneumoniae accelerates the progression of atherosclerosis in apolipoprotein E deficient mice.  J Infect Dis . 1999;  180 238-241
    CrossrefPubMedGoogle Scholar
  • 113 Meier C R, Derby L E, Jick S S, Vasilakis C, Jick H. Antibiotics and risk of subsequent first-time acute myocardial infarction.  JAMA . 1999;  281 427-431
    CrossrefPubMedGoogle Scholar
  • 114 Anderson J L, Muhlestein J B, Carlquist J. et al . Randomized secondary prevention trial of azithromycin in patients with coronary artery disease and serological evidence for Chlamydia pneumoniae infection: the Azithromycin in Coronary Artery Disease: Elimination of Myocardial Infection with Chlamydia (ACADEMIC) study.  Circulation . 1999;  99 1540-1547
    PubMedGoogle Scholar
  • 115 Veldhyuzen van Zanten J O S, Sherman P M. Helicobacter pylori infection as a cause of gastritis, duodenal ulcer, gastric cancer and nonulcer dyspepsia: a systemic overview.  Can Med Assoc J . 1994;  150 177-185
    PubMedGoogle Scholar
  • 116 Sipponen P, Seppala K, Aarynen M, Helske T, Kettunen P. Chronic gastritis and gastroduodenal ulcer: a case control study on risk of coexisting duodenal or gastric ulcer in patients with gastritis.  Gut . 1989;  30 922-929
    PubMedGoogle Scholar
  • 117 Cullen D JE, Collins B J, Christiansen K J, Epis J, Warren J R, Cullen K J. Long term risk of peptic ulcer disease in people with Helicobacter pylori infection: a community-based study.  Gastroenterology . 1993;  104 A60
    PubMedGoogle Scholar
  • 118 Koenig W, Rothenbacher D, Hoffmeister A. et al . Infection with Helicobacter pylori is not a major independent risk factor for stable coronary heart disease.  Circulation . 1999;  100 2326-2331
    PubMedGoogle Scholar
  • 119 Strandberg T E, Tilvis R S, Vuoristo M, Lindroos M, Kosunen T U. Prospective study of Helicobacter pylori seropositivity and cardiovascular diseases in a general elderly population.  BMJ . 1997;  314 317-318
    PubMedGoogle Scholar
  • 120 Wald N J, Law M R, Morris J K, Bagnall A M. Helicobacter pylori infection and mortality from ischaemic heart disease: negative result from a large, prospective study.  BMJ . 1997;  315 1199-1201
    PubMedGoogle Scholar
  • 121 Folsom A R, Nieto J F, Sorlie P, Chambless L E, Graham D Y. for the Atherosclerosis Risk in Communities (ARIC) Study InvestigatorsHelicobacter pylori seropositivity and coronary heart disease incidence.  Circulation . 1998;  98 845-850
    PubMedGoogle Scholar
  • 122 Strachan D P, Mendall M A, Carrington D. et al . Relation of Helicobacter pylori infection to 13-year mortality and incident ischemic heart disease in the Caerphilly Prospective Heart Disease Study.  Circulation . 1998;  98 1286-1290
    CrossrefPubMedGoogle Scholar
  • 123 Danesh J, Peto R. Risk factors for coronary heart disease and infection with Helicobacter pylori: meta-analysis of 18 studies.  BMJ . 1998;  316 1130-1132
    CrossrefPubMedGoogle Scholar
  • 124 Pasceri V, Cammarota G, Patti G. et al . Association of virulent Helicobacter pylori strains with ischemic heart disease.  Circulation . 1998;  97 1675-1679
    PubMedGoogle Scholar
  • 125 Peek R M, Miller G, Tham K T. et al . Heightened inflammatory response and cytokine expression in vivo to CagA+ Helicobacter pylori strains.  Lab Invest . 1995;  71 760-70
    PubMedGoogle Scholar
  • 126 Williams R C. Periodontal disease.  N Engl J Med . 1990;  322 373-382
    PubMedGoogle Scholar
  • 127 Brown L J, Brunelle J A, Kingman A. Periodontal status in the United States, 1988-9: prevalence, extent, and demographic variation.  J Dent Res . 1996;  75 672-683
    PubMedGoogle Scholar
  • 128 Beck J D, Koch G G, Rozier R G, Tudor G E. Prevalence and risk indicators for periodontal attachment loss in a population of old community-dwelling blacks and whites.  J Periodontol . 1991;  61 521-528
    PubMedGoogle Scholar
  • 129 Alpagot T, Wolff L F, Smith Q T, Tran S D. Risk indicators for periodontal disease in a racially diverse urban population.  J Clin Periodontol . 1996;  23 982-988
    PubMedGoogle Scholar
  • 130 Wu T, Trevisan M, Genco R J, Dorn J P, Falkner K L, Sempos C T. Periodontal disease and risk of cerebrovascular disease: the first national health and nutrition examination survey and its follow-up study.  Arch Intern Med . 2000;  160 2749-2755
    CrossrefPubMedGoogle Scholar
  • 131 Hujoel P P, Drangsholt M, Spiekerman C, DeRouen T A. Periodontal disease and coronary heart disease risk.  JAMA . 2000;  284 1406-1410
    CrossrefPubMedGoogle Scholar
  • 132 Worrall B B, DeGraba T J. The genetics of cerebrovascular atherosclerosis.  Seminars in Cerebrovascular Diseases and Stroke . 2002;  2 14-23
    PubMedGoogle Scholar
  • 133 Liao D, Myers R, Hunt S. et al . Family history of stroke and stroke risk. The Family Heart Study.  Stroke . 1997;  28 1908-1912
    PubMedGoogle Scholar
  • 134 Kiely D K, Wolf P A, Cupples L A, Beiser A S, Kannel W B. Familial aggregation of stroke: The Framingham Study.  Stroke . 1993;  24 1366-1371
    PubMedGoogle Scholar
  • 135 Joutel A, Corpechot C, Ducros A. et al . Notch 3 mutation in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), a mendelian condition causing stroke and vascular dementia.  Ann NY Acad Sci . 1997;  826 213-217
    PubMedGoogle Scholar
  • 136 Tjernstrom F, Hellmer G, Nived O, Truedsson L, Sturfelt G. Synergetic effect between interleukin-1 receptor antagonist allele (IL1RN*2) and MHC class II (DR17,DQ2) in determining susceptibility to systemic lupus erythematosus.  Lupus . 1999;  8 103-108
    CrossrefPubMedGoogle Scholar
  • 137 Schrijver H M, Crusius J B, Uitdehaag B M. et al . Association of interleukin-1 beta and interleukin-1 receptor antagonist genes with disease severity in MS.  Neurology . 1999;  52 595-599
    PubMedGoogle Scholar
  • 138 Bioque G, Crusius J B, Koutroubakis I. et al . Allelic polymorphism in IL-1 beta and IL-1 receptor antagonist (IL-1Ra) genes in inflammatory bowel disease.  Clin Exp Immunol . 1995;  102 379-383
    PubMedGoogle Scholar
  • 139 Francis S E, Camp N J, Dewberry R M. et al . Interleukin-1 receptor antagonist gene polymorphism and coronary artery disease [see comments].  Circulation . 1999;  99 861-866
    PubMedGoogle Scholar
  • 140 Iacoviello L, Donati M B, Gattone M. Possible different involvement of interleukin-1 receptor antagonist gene polymorphism in coronary single vessel disease and myocardial infarction [letter; comment].  Circulation . 2000;  101 E193
    PubMedGoogle Scholar
  • 141 Kokkotou E, Philippon V, Gueye-Ndiaye A. et al . Role of the CCR5 delta 32 allele in resistance to HIV-1 infection in West Africa.  J Hum Virol . 1998;  1 469-474
    PubMedGoogle Scholar
  • 142 Taylor M L, Perez-Mejia A, Yamamoto-Furusho J K. et al . Immunologic, genetic and social human risk factors associated to histoplasmosis: studies in the state of Guerrero, Mexico.  Mycopathologia . 1997;  138 137-142
    CrossrefPubMedGoogle Scholar
  • 143 Momiyama Y, Hirano R, Taniguchi H, Nakamura H, Ohsuzu F. The effects of interleukin-1 gene polymorphisms on the development of coronary artery disease associated with Chlamydia pneumoniae infection.  J Am Coll Cardiol . 2001;  38 712-717
    CrossrefPubMedGoogle Scholar
  • 144 Inoue M, Itoh H, Ueda M. et al . Vascular endothelial growth factor (VEGF) expression in human coronary atherosclerotic lesions: possible pathophysiological significance in VEGF in progression of atherosclerosis.  Circulation . 1998;  98 2108-2116
    PubMedGoogle Scholar
  • 145 Schaper W, Buschmann I. VEGF and therapeutic opportunities in cardiovascular disease.  Curr Opin Biotechnol . 1999;  10 541-543
    CrossrefPubMedGoogle Scholar
  • 146 Simons M, Bonow R O, Chronos N A. et al . Clinical trials in coronary angiogenesis: issues, problems, consensus: an expert panel summary.  Circulation . 2000;  102 E73-86
    CrossrefPubMedGoogle Scholar
  • 147 Yuan C, Kerwin W S, Ferguson M S, Polissar N, Zhang S, Cai J, Hatsukami T S. Contrast enhanced high resolution MRI for atherosclerotic carotid artery tissue characterization.  J Magn Reson Imaging . 2002;  15 62-67
    CrossrefPubMedGoogle Scholar
  • 148 Quick H H, Debatin J F, Ladd M E. MR imaging of the vessel wall.  Eur Radiol . 2002;  12 889-900
    CrossrefPubMedGoogle Scholar
  • 149 Yuan C, Zhang S X, Polissar N L. et al . Identification of fibrous cap rupture with magnetic resonance imaging is highly associated with recent transient ischemic attack or stroke.  Circulation . 2002;  105 181-185
    CrossrefPubMedGoogle Scholar
  • 150 Weiss C R, Arai A E, Bui M N. et al . Arterial wall MRI characteristics are associated with elevated serum markers of inflammation in humans.  J Mag Reson Imaging . 2001;  14 698-704
    PubMedGoogle Scholar
  • 151 Schmitz S A, Taupitz M, Wagner S, Wolf K J, Beyersdorff D, Hamm B. Magnetic resonance imaging of atherosclerotic plaques using superparamagnetic iron oxide particles.  J Mag Reson Imaging . 2001;  14 355-361
    CrossrefPubMedGoogle Scholar
      >